Posttransplant adoptive immunotherapy with interleukin-2 in children suffering from neuroectodermal tumors with poor prognosis

Kałwak, Krzysztof; Ussowicz, Marek; Gorczyńska, Ewa; Toporski, Jacek; Turkiewicz, Dominik; Bogusławska-Jaworska, J; Chybicka, Alicja

doi:10.1016/s0041-1345(01)02881-0

Cited by 1 publication

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…regimen, at least in stage IV NBL patients without cytogenetic abnormalities. (12) Nevertheless, relapses were frequent in our study. Therefore, in order to gain a better understanding of the mechanism of IL-2 immunomodulation, we analyzed the effects of our IL-2 schedule on a series of lymphocyte subpopulations and NK cell-mediated activity.…”

Section: Discussioncontrasting

confidence: 48%

“…Biologically, it has been reported that in patients at relapse, NK activity might be defective. (12,15) It has been proved, however, that NBL, PNET, and ES cell lines are sensitive in vitro to NK cell-mediated lysis. (8)(9)(10) A few trials on the clinical use of IL-2 as adoptive immunotherapy in NBL have been performed, with encouraging results.…”

Section: Discussionmentioning

confidence: 99%

“…Recombinant human IL-2 (rHuIL-2) (Proleukin) (Chiron, Amsterdam, The Netherlands) was administered under close clinical surveillance as described. (12) Immunologic studies…”

Section: Il-2 Immunotherapymentioning

confidence: 99%

“…regimen. (12) Nevertheless, it remains unclear whether a higher but transient activation of the immune system after IL-2 i.v. cycles eradicates MRD more effectively than a weaker but continuous stimulation mediated by IL-2 given s.c.…”

Section: Clinical Aspectsmentioning

confidence: 99%

See 3 more Smart Citations

Immunologic Effects of Intermediate-Dose IL-2 i.v. After Autologous Hematopoietic Cell Transplantation in Pediatric Solid Tumors

Kałwak¹,

Ussowicz²,

Gorczyńska³

et al. 2003

Journal of Interferon & Cytokine Research

View full text Add to dashboard Cite

Adoptive immunotherapy with interleukin-2 (IL-2) may control minimal residual disease (MRD) and prevent relapse after autologous hematopoietic cell transplantation (AHCT). The objective of this study was to determine the immunologic effects of intermediate doses of intravenous (i.v.) IL-2 after AHCT in children with poor-prognosis solid tumors. Eleven patients received a median five cycles consisting of escalating doses of IL-2 i.v. for 5 days after a median time interval of 94 days post-AHCT. The phenotype of lymphocyte subsets was investigated before and after each cycle, and parallel determination of natural killer (NK) cell activity was performed. Immunotherapy induced a significant increase in total lymphocyte count (TLC), T, NK, and, to some extent, B cells. Among NK cells, CD56+ bright cells expanded more than CD56+ dim cells. High expansion of CD56+ cells with CD94 inhibitory receptor was observed, whereas no difference was recorded in the number of CD3+ CD56+ and CD8+ CD57+ cells. NK activity stabilized after the first cycle of IL-2 and remained elevated during the study period. Cycles of IL-2 immunotherapy induced repeated significant expansion of T cells and NK cells, mostly of the immature CD56+ bright phenotype. Despite enhanced NK activity, relapses occurred frequently, which might have been due to increased CD94 activation and a poor response from the cytotoxic NK T cells and CD8+ CD57+ T cells.

show abstract

Section: Discussioncontrasting

confidence: 48%

Section: Discussionmentioning

confidence: 99%

“…Recombinant human IL-2 (rHuIL-2) (Proleukin) (Chiron, Amsterdam, The Netherlands) was administered under close clinical surveillance as described. (12) Immunologic studies…”

Section: Il-2 Immunotherapymentioning

confidence: 99%

Section: Clinical Aspectsmentioning

confidence: 99%

See 2 more Smart Citations